Stocks and Investing Stocks and Investing
Wed, May 16, 2018
Tue, May 15, 2018
Mon, May 14, 2018
Fri, May 11, 2018
Thu, May 10, 2018
Wed, May 9, 2018
Tue, May 8, 2018
Mon, May 7, 2018
Fri, May 4, 2018

Alethia Young Maintained (SRPT) at Buy with Decreased Target to $92 on, May 4th, 2018


Published on 2024-10-26 05:22:10 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Decreased Target from $100 to $92 on, May 4th, 2018.

Alethia has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Alethia


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018
  • Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018